We have read with interest the article recently published by Zanetto et al. in Liver Transplantation regarding the effect on radiologic progression of hepatocellular carcinoma (HCC) after the treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) in patients listed for liver transplantation. (1) Although a previous call for attention to a higher, early, and aggressive HCC recurrence following the treatment with DAAs has been observed, (2) Zanetto et al. reported similar outcomes while on the waiting list between patients treated with DAAs and controls in terms of dropout (8.7% versus 4.3%) and HCC radiological progression (35% versus 17%, respectively). Although both studies proposed a novel discussion whether DAAs promote an immunological disruption and tumor growth, its causal inference is still far away to reach robustness.
TO THE EDITOR:
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The radiological HCC progression during the waiting list in previous studies ranges 4%-6% and close to 20% at 6 and 12 months of listing, respectively. (3, 4) The study by Zanetto et al. is limited by the fact that the nonrandom intervention already biases the results, even after adjusting for confounding variables such as serum alpha-fetoprotein values. (5) Likewise, neither the intervention assignment nor the radiological evaluation were blinded from baseline variables. Finally, a sample size estimation is lacking. Observing "nonsignificant" differences in this study might be far away from the real effect as a consequence of this lack of power. In fact, the study published by Roayaie et al. might have gone through the reported confidence interval limits (95% CI of 17% to 40%). (6) Ultimately, although the clinical question is novel, this research does not "illuminate" but rather "deepens the confusion" on this topic and further demands a randomized intervention study. 
